Could Viking Therapeutics Be the Next Eli Lilly? Demand for weight loss drugs may fuel growth for more than one player.
Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight Loss Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.
Best Weight Loss Drug Stocks to Buy in 2026 If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (
NYSE:ELAN ) and its peers. The pha...
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.
Eli Lilly Stock: Next Stop $2,000? The company is riding an incredible tailwind.
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.
Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
Is Kailera Therapeutics a Buy After Its Sizzling IPO? There's a new challenger to the more established players in the weight-loss drug space.
Buy, Sell, or Hold Novo Nordisk at $46? Can Novo Nordisk thrive under intense competitive pressures?
My Top 3 Healthcare Stocks for May 2026 Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook Amphastar Pharmaceuticals (
NASDAQ:AMPH ) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.
Bill Peters, chief financial officer of Amphastar
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies.
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Avoid The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
